Mark Colonnese - Atea PharmaceuticalsI CFO, Executive Vice President
AVIR Stock | USD 3.70 0.03 0.80% |
President
Mr. Mark P. Colonnese is Chief Financial Officer, Executive Vice President of the Company. He served as the Chief Financial Officer of Stealth BioTherapeutics since November 2014 and as the Executive Vice President and Chief Financial Officer of Transgenomic Inc. from August 2012 to October 2014. Prior to that, he worked at Salutria Pharmaceuticals, LLC and at its predecessor company, AtheroGenics Inc., from 1999 to 2012, where he served in a number of executive roles, most recently as Executive Vice President, Commercial Operations and Chief Financial Officer. He has also held executive positions at Applied Analytical Industries and ScheringPlough, and served on the Board of Directors of Endeavor Pharmaceuticals, Inc since 2015.
Age | 60 |
Tenure | 9 years |
Professional Marks | MBA |
Address | 225 Franklin Street, Boston, MA, United States, 02110 |
Phone | 857 284 8891 |
Web | https://ateapharma.com |
Atea PharmaceuticalsI Management Efficiency
The company has return on total asset (ROA) of (0.1189) % which means that it has lost $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2274) %, meaning that it created substantial loss on money invested by shareholders. Atea PharmaceuticalsI's management efficiency ratios could be used to measure how well Atea PharmaceuticalsI manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/24/2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, Atea PharmaceuticalsI's Non Current Assets Total are relatively stable compared to the past year. As of 04/24/2024, Non Currrent Assets Other is likely to grow to about 1.5 M, while Net Tangible Assets are likely to drop slightly above 398.8 M.Similar Executives
Found 3 records | PRESIDENT Age | ||
Kathryn McNaughton | AVROBIO | N/A | |
Birgitte Volck | AVROBIO | 56 | |
Erik MBA | AVROBIO | 52 |
Management Performance
Return On Equity | -0.23 | ||||
Return On Asset | -0.12 |
Atea PharmaceuticalsInc Leadership Team
Elected by the shareholders, the Atea PharmaceuticalsI's board of directors comprises two types of representatives: Atea PharmaceuticalsI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atea. The board's role is to monitor Atea PharmaceuticalsI's management team and ensure that shareholders' interests are well served. Atea PharmaceuticalsI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atea PharmaceuticalsI's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Exec Officer | ||
XiaoJian Zhou, Executive Development | ||
Jayanthi Wolf, Executive Affairs | ||
Wayne CPA, Executive Officer | ||
Anne VanLent, Independent Director | ||
Ariyapadi Krishnaraj, Vice Marketing | ||
Mark Colonnese, CFO, Executive Vice President | ||
Russell Plumb, Executive Chairman of the Board | ||
JeanPierre Sommadossi, Chairman, Founder | ||
John Vavricka, Chief Officer | ||
Geoffrey Cox, Independent Director | ||
Nancy Agrawal, Executive Development | ||
Maria MD, Chief Officer | ||
John Richard, Independent Director | ||
Jonae Barnes, Senior Communications | ||
Andrea JD, Executive CFO | ||
Michael Dunne, Independent Director | ||
Keith Pietropaolo, Senior Sciences | ||
Joseph Patti, President CEO, Director | ||
Adel Moussa, Executive Chemistry | ||
Armando Anido, Independent Director | ||
Michael Dougherty, Independent Director |
Atea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atea PharmaceuticalsI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.23 | ||||
Return On Asset | -0.12 | ||||
Current Valuation | (261.77 M) | ||||
Shares Outstanding | 84.16 M | ||||
Shares Owned By Insiders | 9.46 % | ||||
Shares Owned By Institutions | 67.64 % | ||||
Number Of Shares Shorted | 1.67 M | ||||
Price To Earning | 15.03 X | ||||
Price To Book | 0.57 X | ||||
Price To Sales | 1.90 X |
Pair Trading with Atea PharmaceuticalsI
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.Moving against Atea Stock
0.57 | ACB | Aurora Cannabis Trending | PairCorr |
0.51 | CGC | Canopy Growth Corp Trending | PairCorr |
0.5 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Atea PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea PharmaceuticalsInc to buy it.
The correlation of Atea PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
CEOs Directory Screen CEOs from public companies around the world | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.641 | Earnings Share (1.63) | Revenue Per Share 2.31 | Quarterly Revenue Growth 2.952 | Return On Assets (0.12) |
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.